<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416167</url>
  </required_header>
  <id_info>
    <org_study_id>FYU-981-006</org_study_id>
    <nct_id>NCT02416167</nct_id>
  </id_info>
  <brief_title>Study of FYU-981 in Hyperuricemia With or Without Gout</brief_title>
  <official_title>Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuji Yakuhin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is confirmatory investigation of safety and efficacy (dose response
      and optimal dose according to the percent reduction from baseline in serum urate level at the
      final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout
      for 12 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 8
      weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind,
      parallel group comparison.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction from baseline in serum urate level at the final visit</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>FYU-981 High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FYU-981 High middle dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FYU-981 Middle dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FYU-981 Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FYU-981</intervention_name>
    <arm_group_label>FYU-981 High dose</arm_group_label>
    <arm_group_label>FYU-981 High middle dose</arm_group_label>
    <arm_group_label>FYU-981 Middle dose</arm_group_label>
    <arm_group_label>FYU-981 Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperuricemic or gout patients

          -  Serum urate level:

        &gt;= 7.0mg/dL in patients with history of gout, or &gt;= 8.0mg/dL in patients with hypertension,
        diabetes or metabolic syndrome, or &gt;= 9.0mg/dL

        Exclusion Criteria:

          -  Gouty arthritis within two weeks before start of study treatment

          -  Secondary hyperuricemia

          -  HbA1c: &gt;= 8.4%

          -  Uric acid-overproduction type in the classification of hyperuricemia

          -  History of, clinically significant cardiac, hematologic and hepatic disease

          -  Kidney calculi or clinically significant urinary calculi

          -  eGFR: &lt; 30mL/min/1.73m^2

          -  Systolic blood pressure: &gt;= 180 mmHg

          -  Diastolic blood pressure: &gt;= 110 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Japan</name>
      <address>
        <city>Tokyo and Other Japanese City</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

